HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
HERON THERAPEUTICS, INC. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.36−0.00 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $68.69M
- P/E (TTM)
- –
- Dividend yield
- –
Heron Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Market Cap | $68.52M | $197.05M |
| Enterprise Value | $25.82M | $106.56M |
| PS Ratio | 0.45 | 3.93 |
| PB Ratio | 9.92 | 2.14 |
| P/TBV Ratio | 9.92 | 2.46 |
Enterprise value
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.17 | 2.69 |
Income (trailing twelve months)
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Revenue | $151.18M | $57.94M |
| Gross Profit | $105.94M | $90.47M |
| Operating Income | -$10.86M | -$21.44M |
| Net Income | -$34.05M | -$22.46M |
| EBITDA | -$8.73M | -$16.91M |
| EPS (Diluted) | -$0.19 | -$0.83 |
Margins
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 70.1% | 52.3% |
| Operating Margin | -7.19% | -44.5% |
| Profit Margin | -22.5% | -39.2% |
| EBITDA Margin | -5.78% | -31.3% |
| FCF Margin | -8.03% | -8.85% |
Returns
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -14.1% | -41.0% |
| Return on Capital Employed (ROCE) | -6.79% | -37.8% |
Growth
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 0.99% | 6.01% |
| Revenue Growth (3Y CAGR) | 12.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 11.8% | 6.42% |
Balance sheet
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $42.70M | $62.42M |
| Net Cash (Debt) | $42.70M | $15.68M |
| Net Cash Per Share | $0.22 | $0.65 |
| Equity (Book Value) | $6.91M | $48.79M |
| Book Value Per Share | $0.04 | $1.36 |
| Tangible Book Value | $6.91M | $23.06M |
| Working Capital | $137.70M | $75.77M |
Financial position
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.49 | 3.30 |
| Quick Ratio | 1.44 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.61M | -$12.35M |
| Capital Expenditures | -$529.00K | -$1.06M |
| Free Cash Flow | -$12.14M | -$20.28M |
| FCF Per Share | -$0.06 | -$0.41 |
Efficiency
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.62 | 0.38 |
| Inventory Turnover | 0.55 | 2.67 |
| Revenue Per Employee | $1.18M | $398.96K |
| Profits Per Employee | -$266.01K | -$732.08K |
| Employee Count | 128 | 73 |
Dividends and yields
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -49.7% | -21.2% |
| FCF Yield | -17.7% | -7.64% |
Shares
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 189,852,000 | 59,128,900 |
| Shares Change (YoY) | 12.4% | 11.1% |
| Float | 149,021,000 | 48,744,500 |
| Shares Held by Insiders | 21.5% | 11.8% |
| Shares Held by Institutions | 70.4% | 59.4% |
Scores
| Measure | Heron Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -9.56 | 0.10 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.41 | -2.62 |
Calculated by StockData from Heron Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.